HAINAN SHUANGCHENG PHARMACEUTICALS CO., LTD. Financials Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Equities
002693
CNE100001K63
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.5 CNY | -2.83% |
|
-10.28% | -26.76% |
| 07:43am | Workshop of Shuangcheng Pharma's Unit Passes Regulatory Inspection; Shares Up 3% | MT |
| 05-07 | Shuangcheng Pharma Gets FDA Nod to Market Acromegaly Drug in US | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,575 | 1,887 | 1,754 | 1,945 | 3,015 | 3,129 |
| Enterprise Value (EV) 1 | 1,679 | 1,959 | 1,876 | 2,035 | 3,092 | 3,242 |
| P/E ratio | -22.9 x | 77.7 x | -33.3 x | -94.4 x | 364 x | -62.6 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 4.67 x | 5.44 x | 6.51 x | 6.07 x | 11 x | 13.3 x |
| EV / Revenue | 4.98 x | 5.65 x | 6.96 x | 6.35 x | 11.3 x | 13.7 x |
| EV / EBITDA | -83.6 x | 189 x | -873 x | 626 x | 262 x | 107 x |
| EV / FCF | 11.7 x | 14.6 x | -86 x | 51 x | -141 x | 117 x |
| FCF Yield | 8.55% | 6.85% | -1.16% | 1.96% | -0.71% | 0.86% |
| Price to Book | 3.02 x | 3.45 x | 3.56 x | 4.04 x | 5.87 x | 7.08 x |
| Nbr of stocks (in thousands) | 405,000 | 405,000 | 405,000 | 412,000 | 414,737 | 416,631 |
| Reference price 2 | 3.890 | 4.660 | 4.330 | 4.720 | 7.270 | 7.510 |
| Announcement Date | 18/04/19 | 28/04/20 | 20/04/21 | 07/04/22 | 20/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 337.2 | 346.6 | 269.4 | 320.3 | 274.8 | 235.9 |
| EBITDA 1 | -20.08 | 10.37 | -2.149 | 3.248 | 11.79 | 30.32 |
| EBIT 1 | -74.53 | -47.03 | -60.35 | -49.62 | -44.24 | -22.35 |
| Operating Margin | -22.1% | -13.57% | -22.4% | -15.49% | -16.1% | -9.47% |
| Earnings before Tax (EBT) 1 | -93.36 | 10.52 | -78.78 | -40.36 | -8.881 | -72.97 |
| Net income 1 | -69.46 | 24.66 | -53.33 | -20.33 | 9.012 | -50.74 |
| Net margin | -20.6% | 7.11% | -19.79% | -6.35% | 3.28% | -21.51% |
| EPS 2 | -0.1700 | 0.0600 | -0.1300 | -0.0500 | 0.0200 | -0.1200 |
| Free Cash Flow 1 | 143.5 | 134.2 | -21.81 | 39.87 | -21.89 | 27.83 |
| FCF margin | 42.55% | 38.7% | -8.09% | 12.45% | -7.97% | 11.79% |
| FCF Conversion (EBITDA) | - | 1,293.31% | - | 1,227.73% | - | 91.77% |
| FCF Conversion (Net income) | - | 544.12% | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 18/04/19 | 28/04/20 | 20/04/21 | 07/04/22 | 20/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 104 | 71.5 | 122 | 90 | 77.4 | 113 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -5.163 x | 6.895 x | -56.94 x | 27.7 x | 6.561 x | 3.731 x |
| Free Cash Flow 1 | 143 | 134 | -21.8 | 39.9 | -21.9 | 27.8 |
| ROE (net income / shareholders' equity) | -12.9% | 1.34% | -12.5% | -7.01% | -1.48% | -13.1% |
| ROA (Net income/ Total Assets) | -3.73% | -2.84% | -4.06% | -3.52% | -3.13% | -1.63% |
| Assets 1 | 1,862 | -868.7 | 1,314 | 577.5 | -287.7 | 3,114 |
| Book Value Per Share 2 | 1.290 | 1.350 | 1.220 | 1.170 | 1.240 | 1.060 |
| Cash Flow per Share 2 | 0.1700 | 0.1100 | 0.0100 | 0.0500 | 0.0300 | 0.0100 |
| Capex 1 | 22.4 | 51.5 | 51.6 | 31.6 | 33 | 49.2 |
| Capex / Sales | 6.64% | 14.86% | 19.14% | 9.88% | 12% | 20.85% |
| Announcement Date | 18/04/19 | 28/04/20 | 20/04/21 | 07/04/22 | 20/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -26.76% | 317M | |
| +20.66% | 44.39B | |
| +20.08% | 22.46B | |
| +18.66% | 15.04B | |
| +19.35% | 13.98B | |
| +55.96% | 13.15B | |
| -10.55% | 6.89B | |
| -0.05% | 6.79B | |
| +14.03% | 5.71B | |
| -8.87% | 5.73B |
- Stock Market
- Equities
- 002693 Stock
- Financials Hainan Shuangcheng Pharmaceuticals Co., Ltd.
